Elutia (NASDAQ:ELUT – Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown of current […]
Perkins Capital Management Inc. lifted its stake in Elutia Inc. (NASDAQ:ELUT – Free Report) by 26.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 348,948 shares of the company’s stock after purchasing an additional 73,619 shares during the quarter. Perkins Capital Management […]
Perkins Capital Management Inc. lifted its position in Elutia Inc. (NASDAQ:ELUT – Free Report) by 26.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 348,948 shares of the company’s stock after buying an additional 73,619 shares during the period. Perkins Capital Management Inc.’s holdings in […]
Lake Street Capital began coverage on shares of Elutia (NASDAQ:ELUT – Free Report) in a research report sent to investors on Thursday, Marketbeat reports. The firm issued a buy rating on the stock. Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $8.00 price objective on shares of Elutia in a research report on […]
Lake Street Capital began coverage on shares of Elutia (NASDAQ:ELUT – Free Report) in a research note released on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating on the stock. Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $8.00 price target on shares of Elutia in a research note on Tuesday, […]